T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V?3, V?14, and V?17 Peptides

199873 citationsJournal Article

Authors

Larry W. Moreland · University of Alabama at Birmingham

Elizabeth E. Morgan · Response Technologies (United States)

T. C. Adamson · Sharp Rees-Stealy Medical Group

Zdenka Fronek · Sharp Rees-Stealy Medical Group

Leonard H. Calabrese · Cleveland Clinic

Joseph M. Cash · University of Alabama at Birmingham

Joseph A. Markenson

Abstract

IR501 therapeutic vaccine therapy was safe and well tolerated, immunogenic, and demonstrated clinical improvement in RA patients. Additional clinical trials are planned to confirm and extend these observations.

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Monoclonal and Polyclonal Antibodies Research vaccines and immunoinformatics approaches

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Arthritis & Rheumatism

Volume 41, Issue 11, pp. 1919-1929

DOI: 10.1002/1529-0131(199811)41:11<1919::aid-art5>3.0.co;2-1

Field-Weighted Citation Impact: 6.29